Camurus AB (CHIX:CAMXS) Short Ratio

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:CAMXS Camurus AB CHIX:CAMXS
86 GF Score
Price kr615.75
GF Value kr662.34
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Camurus AB Short Ratio?

Short Ratio is a metric signaling prevailing investors' sentiment with a company. It represents the number of days it takes short sellers on average to repurchase all the shares short.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

CHIX:CAMXS
86GF Score
Camurus AB CHIX:CAMXS
Short Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Camurus AB (CHIX:CAMXS) Overvalued in 2026?

Based on GuruFocus' analysis, Camurus AB stock appears to be undervalued. The current stock price of kr615.75 is trading 7% below its estimated GF Value™ of kr662.34. GuruFocus considers Camurus AB to be Fairly Valued.

Key valuation signals for CHIX:CAMXS:

  • Short Ratio:
  • GF Value™: kr662.34 vs. price of kr615.75 (7% below fair value)
  • GF Score™: 86/100 with 2 warning signs

No single metric tells the full story. See the CHIX:CAMXS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Camurus AB Business Description

Address Rydbergs torg 4, Lund, SWE, SE-224 84
Camurus AB is a science-led biopharmaceutical company focused on developing and commercializing long-acting medicines for the treatment of severe and chronic diseases. It has two approved products, including treatments for opioid dependence, and a development pipeline supported by its FluidCrystal technology. Its clinical pipeline includes product candidates for conditions such as pain, cancer, endocrine, and metabolic diseases, developed in-house and in collaboration with international pharmaceutical companies. Its pipeline programs include CAM2029 for acromegaly, gastroenteropancreatic neuroendocrine tumors, and polycystic liver disease; CAM2038 for chronic pain; CAM4072 for genetic obesity disorders; CAM2043 for Raynaud's phenomenon; CAM4071 for endocrine disorders, among others.
86GF Score

Get the complete analysis for CHIX:CAMXS

Short Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr615.75
Price
kr662.34
GF Value